Skip to main content
Clinical Trials/NCT01444573
NCT01444573
Unknown
Phase 3

Rate Ventricular Control Therapy by Implantable Continuous Monitor in Patients With Permanent Atrial Fibrillation

Meshalkin Research Institute of Pathology of Circulation1 site in 1 country90 target enrollmentSeptember 2011

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Atrial Fibrillation
Sponsor
Meshalkin Research Institute of Pathology of Circulation
Enrollment
90
Locations
1
Primary Endpoint
Hospitalization for all cardio-vascular events
Last Updated
10 years ago

Overview

Brief Summary

The investigators hypothesized that very lenient rate control is not inferior to strict or lenient rate control assessed by implantable continuous ECG monitor for preventing cardiovascular hospitalization and mortality in patients with long-standing persistent or permanent atrial fibrillation

Registry
clinicaltrials.gov
Start Date
September 2011
End Date
September 2015
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Meshalkin Research Institute of Pathology of Circulation
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Long-standing persistent or permanent atrial fibrillation
  • Mean resting heart rate \> 80 beats per minute with or without rate control medication
  • Age \< 70 years old
  • Constant use of anticoagulation therapy

Exclusion Criteria

  • Paroxysmal or persistent atrial fibrillation
  • Non-stable heart failure or \> III NYHA FC
  • Indications for IPG/CRT/ICD
  • Thyroid dysfunction
  • Inability to walk or bike.

Outcomes

Primary Outcomes

Hospitalization for all cardio-vascular events

Time Frame: 12 months

Secondary Outcomes

  • All-cause death(12 months)
  • stroke(12 months)
  • life-threatening arrhythmic and drugs adverse events(12 months)

Study Sites (1)

Loading locations...

Similar Trials